Xian Hanfeng Pharmaceutical Co. Ltd.

Primary objective: To study the pharmacokinetics of the test preparation Nicorandil Tablets 5 mg (produced by Xi'an Hanfeng Pharmaceutical Co., Ltd.) and the reference preparation Nicorandil Tablets 5 mg (produced by Chugai Pharmaceutical Co., Ltd., trade name: Sigma®) in healthy subjects in the fasting and postprandial states, and to evaluate the bioequivalence of the two preparations in the fasting and postprandial states. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Primary objective: To study the pharmacokinetics of the test preparation nicorandil tablets 5 mg and the reference preparation nicorandil tablets 5 mg (produced by Chugai Pharmaceutical Co., Ltd., trade name: Sigma®) in healthy volunteers after oral administration in the fed state, and to evaluate the intra-individual variation of the reference preparation and the bioequivalence between the test preparation and the reference preparation when administered in the fed state. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Primary objective: To evaluate the bioequivalence of amlodipine besylate tablets versus NORVASC® under fed conditions. Secondary objectives: To evaluate other pharmacokinetic (PK) variables. As safety indicators, adverse events (AEs), physical examination, laboratory tests, electrocardiograms, and vital signs (sitting blood pressure, pulse, and temperature) will be recorded.